(:MDCO)
Business Focus: N/A
Jan 06, 2020 01:12 pm ET
The Medicines Company Announces Effective Date Of Make-Whole Fundamental Change Relating To Its 2.50% Convertible Senior Notes Due 2022, 2.75% Convertible Senior Notes due 2023 and 3.50% Convertible S
The Medicines Company (the “Company”) today provided notice of a Make-Whole Fundamental Change to holders of its (i) 2.50% Convertible Senior Notes due 2022 (the “2022 Notes”), (ii) 2.75% Convertible Senior Notes due 2023 (the “2023 Notes”) and (ii) 3.50% Convertible Senior Notes due 2024 (the “2024 Notes,” and collectively with the 2022 Notes and 2023 Notes, the “Notes”). The consummation of the previously announced transactions contemplated by the Agreement and Plan of Merger, dated as of November 23, 2019 (the “Merger Agreement”), by and among the Company, Novartis AG (the “Parent”) and Med
Dec 24, 2019 11:03 am ET
SHAREHOLDER ALERT: WeissLaw LLP Reminds CISN, AXE, MDCO, and WLH Shareholders About Its Ongoing Investigations
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP 1500 Broadway, 16th...
Dec 10, 2019 09:30 pm ET
BOLD, MDCO, AYR, and PEGI SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts
Rigrodsky & Long, P.A. announces that it is investigating: Audentes Therapeutics, Inc. (NASDAQ GS: BOLD) regarding possible breaches of fiduciary duties and other violations of law related to Audentes Therapeutics’ agreement to be acquired by...
Dec 10, 2019 11:46 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders – MDCO, TIF, AMTD, CARO
Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: The Medicines Company (NASDAQ: MDCO)The investigation concerns whether The Medicines Company and its board of directors violated the federal...
Dec 04, 2019 08:00 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders – AMTD, TIF, MDCO, PGNX
Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: TD Ameritrade Holding Corporation (NASDAQ: AMTD)The investigation concerns whether TD Ameritrade and its board of directors violated the federal...
Dec 03, 2019 11:00 pm ET
MDCO, IPHS, BREW, and CARB SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts
Rigrodsky & Long, P.A. announces that it is investigating: The Medicines Company (NASDAQ GS: MDCO) regarding possible breaches of fiduciary duties and other violations of law related to The Medicines Company’s agreement to be acquired by Novartis...
Nov 25, 2019 12:09 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of The Medicines Company to Novartis AG is Fair to Shareholders
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased The Medicines Company (the “Company”) (NASDAQ: MDCO) stock prior to November 24, 2019. You are hereby notified that Levi & Korsinsky, LLP...
Nov 25, 2019 11:26 am ET
Shareholder Investigation Alert: Halper Sadeh LLP Investigates Whether the Sale of These Companies is Fair to Shareholders – MDCO, AMTD, TIF, BREW
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: The Medicines Company (NASDAQ: MDCO)The investigation concerns whether The Medicines Company and its board of directors violated the...
Nov 24, 2019 03:05 pm ET
The Medicines Company Enters Into Definitive Agreement to be Acquired by Novartis AG for $9.7 Billion
The Medicines Company (NASDAQ: MDCO) announced today that it has entered into definitive agreement in which Novartis AG will acquire The Medicines Company for $85 per share in an all-cash transaction, implying a fully diluted equity value of $9.7 billion. The price represents a premium of approximately 45% to The Medicines Company’s closing share price of $58.65 on November 18, 2019 (the last trading day prior to news reports of a potential transaction between The Medicines Company and Novartis AG). The transaction was unanimously approved by the Boards of Directors of both companies.
Nov 18, 2019 09:00 am ET
The Medicines Company Announces that the ORION-9 Study of Inclisiran in HeFH Patients Showed Durable and Potent LDL-C Lowering with Twice-Yearly Dosing
The Medicines Company (NASDAQ: MDCO) today announced detailed results from ORION-9, the last of three pivotal 18-month low-density lipoprotein cholesterol (LDL-C) lowering Phase 3 clinical studies of inclisiran, an investigational twice-yearly therapy to reduce LDL-C and the first and only cholesterol-lowering treatment in the siRNA (small-interfering RNA) class. In ORION-9, twice-yearly dosing (following initial and three-month doses) with inclisiran sodium 300 mg met all primary and secondary efficacy endpoints, was well-tolerated and demonstrated an excellent safety profile. Full study resu
Nov 16, 2019 10:45 am ET
The Medicines Company Announces that the ORION-10 Study of Inclisiran in ASCVD Patients Showed Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing
The Medicines Company (NASDAQ: MDCO) today announced detailed results from ORION-10, the second of three pivotal 18-month low-density lipoprotein cholesterol (LDL-C) lowering Phase 3 clinical studies of inclisiran, an investigational twice-yearly therapy to reduce LDL-C and the first and only cholesterol-lowering treatment in the siRNA (small-interfering RNA) class. In ORION-10, twice-yearly dosing with inclisiran sodium 300 mg met all primary and secondary efficacy endpoints, was well-tolerated and again demonstrated an excellent safety profile. Full study results were presented during a late
Nov 06, 2019 04:30 pm ET
The Medicines Company to Present Inclisiran Data from ORION-9 and ORION-10 Pivotal Phase 3 Clinical Studies at American Heart Association Scientific Sessions 2019
The Medicines Company (NASDAQ:MDCO) today announced that detailed results from the ORION-9 and ORION-10 pivotal Phase 3 clinical studies of inclisiran will be presented during late-breaking science sessions at the American Heart Association (AHA) Scientific Sessions 2019, November 16-18, in Philadelphia. The Company will also be hosting and sponsoring educational sessions (
Oct 30, 2019 07:00 am ET
The Medicines Company Reports Third-Quarter 2019 Financial Results and Achievement of Major Milestones for Inclisiran
The Medicines Company (NASDAQ: MDCO) today reported financial results for the third quarter that ended September 30, 2019. Third-quarter highlights included successful completion of pivotal Phase 3 LDL cholesterol (LDL-C) lowering clinical trials for inclisiran with presentation of efficacy and safety data for ORION-11 at the European Society of Cardiology’s ESC Congress 2019 and announcement of topline results for ORION-9 and ORION-10. Each study met all primary and secondary endpoints, showing durable and potent efficacy with twice-yearly dosing of inclisiran and excellent safety with no tre
Oct 24, 2019 04:30 pm ET
The Medicines Company to Announce Third Quarter 2019 Financial Results on October 30
The Medicines Company (NASDAQ: MDCO) will host a conference call and audio webcast on Wednesday, October 30, 2019 at 8:30 a.m. EDT to discuss its third quarter 2019 financial results and operational developments.
Oct 04, 2019 11:00 am ET
The Medicines Company to Participate in the Chardan 3rd Annual Genetic Medicines Conference
The Medicines Company (NASDAQ:MDCO) announced that it will participate in the Chardan 3rd Annual Genetic Medicines Conference on Tuesday, October 8, 2019, in New York. The Company is scheduled to participate in a “fireside chat” discussion at 8:00 a.m. Eastern Daylight Time.
Sep 25, 2019 07:05 am ET
The Medicines Company Announces Positive Topline Results for ORION-10 Phase 3 Study of Inclisiran in ASCVD Patients
The Medicines Company (NASDAQ: MDCO) today announced positive topline results for the ORION-10 Phase 3 clinical study in patients with atherosclerotic cardiovascular disease (ASCVD), successfully completing the pivotal Phase 3 LDL-cholesterol (LDL-C) lowering clinical trials for inclisiran. ORION-10 met all primary and secondary endpoints, and inclisiran demonstrated efficacy, tolerability and safety that were at least as favorable as observed in ORION-11, with no treatment-related liver or renal laboratory abnormalities.
Sep 25, 2019 07:00 am ET
The Medicines Company Announces Positive Topline Results for ORION-9 Phase 3 Study of Inclisiran in Heterozygous Familial Hypercholesterolemia Patients
The Medicines Company (NASDAQ: MDCO) today announced positive topline results for the ORION-9 Phase 3 clinical study in patients with Heterozygous Familial Hypercholesterolemia (HeFH). ORION-9 met all primary and secondary endpoints, and inclisiran demonstrated durable and potent efficacy and was well-tolerated with excellent safety that was generally well-balanced between the treatment groups. Furthermore, there were no treatment-related liver or renal laboratory abnormalities.
Sep 03, 2019 09:31 am ET
Thinking about buying stock in Cidara Therapeutics, Canopy Growth, Generac, Lowe's, or Medicines Co?
NEW YORK, Sept. 3, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CDTX, CGC, GNRC, LOW, and MDCO.
Sep 02, 2019 02:30 am ET
The Medicines Company Presents Results from ORION-11, First Phase 3 Trial of Inclisiran, Showing Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing
The Medicines Company (NASDAQ: MDCO) today announced the presentation of results from ORION-11, its first pivotal Phase 3 clinical study of inclisiran, an investigational twice-yearly therapy to reduce low-density lipoprotein cholesterol (LDL-C) and the first and only cholesterol-lowering therapy in the siRNA (small-interfering RNA or “sir-nah”) class. In ORION-11, twice-yearly dosing with inclisiran sodium 300 mg met all primary and secondary efficacy endpoints, was well-tolerated and demonstrated an excellent safety profile. Full study results were presented today during a late-breaking scie
Aug 26, 2019 07:00 am ET
The Medicines Company Announces Positive Topline Results from First Pivotal Phase 3 Trial of Inclisiran
The Medicines Company (NASDAQ: MDCO) today announced positive topline results from the first pivotal Phase 3 clinical trial evaluating the efficacy, safety, and tolerability of inclisiran to decrease LDL-cholesterol (LDL-C) through twice-yearly dosing. The ORION-11 study of inclisiran sodium 300 mg met all primary and secondary endpoints with efficacy consistent with findings from Phase 1 and 2 studies. The trial showed that inclisiran was well tolerated and confirmed that the safety profile was at least as favorable as that demonstrated in the ORION-1 Phase 2 and ORION-3 open label extension
Jul 24, 2019 07:00 am ET
The Medicines Company Reports Second-Quarter 2019 Financial Results and Updates Clinical Development Program
The Medicines Company (NASDAQ: MDCO) today reported financial results for the second quarter that ended June 30, 2019. Second quarter highlights included significant progress with the clinical development program for inclisiran and the completion of a public offering of common stock.
Jul 24, 2019 06:30 am ET
The Medicines Co. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / July 24, 2019 / The Medicines Co. (NASDAQ: MDCO) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 24, 2019 at 8:30 AM Eastern Time.
Jul 17, 2019 07:00 am ET
The Medicines Company to Announce Second Quarter 2019 Financial Results on July 24
The Medicines Company (NASDAQ: MDCO) will host a conference call and audio webcast on Wednesday, July 24, 2019 at 8:30 a.m. EDT to discuss its second quarter 2019 financial results and operational developments.
Jun 25, 2019 10:30 pm ET
The Medicines Company Announces Pricing of Public Offering of Common Stock
The Medicines Company (NASDAQ:MDCO) (the “Company”) today announced the pricing of a public offering of 4,545,455 shares of its common stock at a public offering price of $33.00 per share. Gross proceeds of the offering are expected to be approximately $150 million, before underwriting discounts and commissions and other transaction expenses. In addition, the underwriters have been granted a 30-day option to purchase from the Company up to an additional 681,818 shares of common stock. The Company expects to use the net proceeds of the offering to fund its development of inclisiran and for gene
Jun 24, 2019 05:30 pm ET
The Medicines Company Announces Launch of Public Offering of Common Stock
The Medicines Company (NASDAQ:MDCO) (the “Company”) today announced the launch of a public offering of $150.0 million of shares of its common stock. In addition, the underwriters will be granted a 30-day option to purchase from the Company up to an additional $22.5 million of shares of common stock. The Company expects to use the net proceeds of the offering to fund its development of inclisiran and for general corporate purposes.
May 27, 2019 10:21 am ET
The Medicines Company Presents Clinical Data Analyses for Inclisiran at 87th European Atherosclerosis Society Congress
The Medicines Company (NASDAQ: MDCO) today announced presentation of
analyses of two clinical studies of inclisiran at the 87th
European Atherosclerosis Society (EAS) Congress in Maastricht,
Netherlands. A combined analysis (N=279) from the Phase 2 ORION-1 and
Phase 1 ORION-7 trials, presented during an e-poster session,
demonstrated that patients across a range of renal function levels
achieved consistent reductions in low-density lipoprotein cholesterol
(LDL-C) with no dose adjustment necessary for patients with renal
impairm
May 20, 2019 09:02 am ET
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating The Medicines Company for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK, May 20, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of The Medicines Company (NASDAQ: MDCO).
May 18, 2019 04:50 pm ET
New Long-Term Data Show that Twice-a-Year Dosing with Inclisiran Results in Persistent Lowering of LDL Cholesterol with No Material Safety Observations Out to Three Years
The Medicines Company (NASDAQ: MDCO) today announced interim results
from the ongoing ORION-3 open-label extension study (Group 1, n=290)
which showed that twice-a-year dosing with inclisiran sodium 300 mg
resulted in consistent lowering of low density lipoprotein cholesterol
(LDL-C) by more than 50 percent with overall follow-up of up to three
years. Inclisiran was well tolerated, and no material safety issues were
observed in the study. These results were presented today during a
late-breaking clinical trial session at the National Lipid Assoc
May 10, 2019 07:00 am ET
The Medicines Company to Host Investor Conference Call and Webcast During National Lipid Association’s 2019 Scientific Sessions
The Medicines Company (NASDAQ:MDCO) will host a conference call and
webcast for investors on Saturday, May 18, 2019, at 5:30 p.m. EDT.
During the call, the Company’s management and clinical trial
investigators will review interim results on the long-term safety and
efficacy data of inclisiran from the ongoing ORION-3 study. The data
will be presented during the late-breaking clinical trial session
earlier the same day at the National Lipid Association (NLA) 2019
Scientific Sessions in Miami.
May 07, 2019 07:00 am ET
The Medicines Company to Participate in the Bank of America Merrill Lynch 2019 Healthcare Conference
The Medicines Company (NASDAQ:MDCO) announced that it will participate
in the Bank of America Merrill Lynch 2019 Healthcare Conference on
Tuesday, May 14, 2019, in Las Vegas. The Company is scheduled to present
at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time).
Apr 25, 2019 07:00 am ET
The Medicines Company Reports First-Quarter 2019 Financial Results and Significant Progress with the Inclisiran Clinical Development Program
The Medicines Company (NASDAQ:MDCO) today reported financial results for
the first quarter that ended March 31, 2019. The first quarter was
marked by significant progress with the inclisiran clinical development
program.
Apr 18, 2019 07:00 am ET
The Medicines Company to Announce First Quarter 2019 Financial Results on April 25
The Medicines Company (NASDAQ:MDCO) will host a conference call and
audio webcast on Thursday, April 25, 2019 at 8:30 a.m. EDT to discuss
its first quarter 2019 financial results and operational developments.
Feb 27, 2019 07:00 am ET
The Medicines Company Reports Fourth-Quarter and Full Year 2018 Business and Financial Results
The Medicines Company (NASDAQ: MDCO) today reported its financial
results for the fourth quarter and full year ended December 31, 2018.
Feb 21, 2019 07:00 am ET
The Medicines Company Announces Upcoming Investor Conference Presentations
The Medicines Company (NASDAQ:MDCO) announced today that management will
present company overviews at the following conferences:
Feb 20, 2019 07:00 am ET
The Medicines Company to Announce Fourth-Quarter and Full-Year 2018 Financial Results on February 27
The Medicines Company (NASDAQ:MDCO) will host a conference call and
audio webcast on Wednesday, February 27, 2019, at 8:30 a.m. EST to
discuss its fourth-quarter and full-year 2018 financial results and
operational developments.
Jan 30, 2019 08:10 am ET
Factors of Influence in 2019, Key Indicators and Opportunity within Leidos, Nomad Foods, Huron Consulting Group, Casella Waste, The Medicines, and Aurinia Pharmaceuticals — New Research Emphasizes Eco
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Leidos Holdings, Inc. (NYSE:LDOS), Nomad Foods Limited (NYSE:NOMD),...
Jan 07, 2019 07:30 am ET
The Medicines Company Announces 5th Review of Un-blinded Data and Recommendation by Independent Data Monitoring Committee to Continue Inclisiran Phase 3 Trials
The Medicines Company (NASDAQ: MDCO) today announced that the 5th
review of un-blinded safety and efficacy data by the Independent Data
Monitoring Committee (IDMC) for inclisiran Phase 3 trials has been
completed. The IDMC has once again recommended that the trials continue
as designed and conducted, without modification.
Dec 13, 2018 09:43 pm ET
The Medicines Company Prices $150 Million of Convertible Notes
The Medicines Company (NASDAQ:MDCO) (the “Company”) today announced that
it has priced its private offering of $150 million in aggregate
principal amount of its convertible senior notes due 2024. The notes
will be sold only to qualified institutional buyers pursuant to Rule
144A under the Securities Act of 1933, as amended. The notes will be
senior unsecured obligations of the Company and will mature on January
15, 2024, unless earlier converted or repurchased in accordance with
their terms. The notes will bear interest at a rate of 3.50% per ye
Dec 12, 2018 04:30 pm ET
The Medicines Company Announces Intention to Offer $150 Million of Convertible Notes
The Medicines Company (NASDAQ:MDCO) (the “Company”) today announced that
it proposes to offer $150 million aggregate principal amount of
convertible senior notes due 2024, subject to market conditions and
other factors. The notes are to be offered and sold only to qualified
institutional buyers pursuant to Rule 144A under the Securities Act of
1933, as amended. The notes will be convertible, upon certain
conditions, into cash, shares of the Company’s common stock or a
combination thereof, at the Company’s option. The interest rate,
conver
Dec 11, 2018 07:23 am ET
The Medicines Company Appoints Mark Timney as Chief Executive Officer
The Medicines Company (NASDAQ: MDCO) today announced that its Board of
Directors has appointed Mark Timney as the Company’s new Chief Executive
Officer and a member of the Board of Directors, effective immediately.
Mr. Timney will succeed Clive Meanwell, M.D., Ph.D., who has been
appointed by the Board to serve as Chief Innovation Officer.
Nov 09, 2018 10:15 am ET
Company Profile for The Medicines Company
The Medicines Company is a biopharmaceutical company driven by an
overriding purpose – to save lives, alleviate suffering and contribute
to the economics of healthcare. The Company’s goal is to create
transformational solutions to address the most pressing healthcare needs
facing patients, physicians and providers in cardiovascular care.
Nov 08, 2018 07:00 am ET
The Medicines Company Reports Third-Quarter 2018 Results
The Medicines Company (NASDAQ:MDCO) today reported its financial results
for the third quarter ended September 30, 2018.
Nov 05, 2018 07:40 am ET
Report: Exploring Fundamental Drivers Behind SkyWest, Blueprint Medicines, HP, Hewlett Packard Enterprise, Cardinal Health, and The Medicines — New Horizons, Emerging Trends, and Upcoming Developments
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SkyWest, Inc. (NASDAQ:SKYW), Blueprint Medicines Corporation...
Nov 01, 2018 07:00 am ET
The Medicines Company to Announce Third-Quarter 2018 Financial Results on November 8
The Medicines Company (NASDAQ:MDCO) will host a conference call and
audio webcast on Thursday, November 8, 2018, at 8:30 a.m., EST, to
discuss its third-quarter 2018 financial results and operational
developments.
Oct 15, 2018 09:10 am ET
Investor Expectations to Drive Momentum within Fossil Group, The Medicines, BWX Technologies, PVH, Group 1 Automotive, and Assurant — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Fossil Group, Inc. (NASDAQ:FOSL), The Medicines Company (NASDAQ:MDCO),...
Oct 01, 2018 07:00 am ET
The Medicines Company Announces Recommendation by Independent Data Monitoring Committee to Continue Inclisiran Phase III Trials Following Fourth Review of Unblinded Data
The Medicines Company (NASDAQ:MDCO) today announced that the Independent
Data Monitoring Committee (IDMC) for the ongoing inclisiran Phase III
trials has recommended that the trials continue as designed and
conducted, without modification. The IDMC’s recommendation was based on
its planned review of unblinded safety and efficacy data from the trials.
Aug 14, 2018 08:30 am ET
Report: Exploring Fundamental Drivers Behind EnLink Midstream, CENTENNIAL RES, Mondelez International, Pacific Premier, Farmland Partners, and The Medicines — New Horizons, Emerging Trends, and Upcomi
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of EnLink Midstream, LLC (NYSE:ENLC), CENTENNIAL RES (NASDAQ:CDEV), Mondelez...
Aug 01, 2018 07:00 am ET
The Medicines Company Reports Second-Quarter 2018 Results
The Medicines Company (NASDAQ:MDCO) today reported its financial results
for the second quarter ended June 30, 2018.
Jul 26, 2018 07:00 am ET
The Medicines Company to Announce Second-Quarter 2018 Financial Results on August 1
The Medicines Company (NASDAQ:MDCO) will host a conference call and
audio webcast on Wednesday, August 1, 2018, at 8:30 a.m. EDT to discuss
its second-quarter 2018 financial results and operational developments.
Jun 27, 2018 07:00 am ET
The Medicines Company Announces Recommendation by Independent Data Monitoring Committee to Continue Inclisiran Phase III Trials Following [Third] Review of Unblinded Data
The Medicines Company (NASDAQ: MDCO) today announced that the
Independent Data Monitoring Committee (IDMC) for the ongoing inclisiran
Phase III trials has recommended that the trials continue as designed
and conducted, without modification. The IDMC’s recommendation was based
on its planned review of unblinded safety and efficacy data from the
trials.
Jun 26, 2018 07:00 am ET
New Data Presented at the American Diabetes Association 78th Scientific Sessions® Reinforce the Potential of The Medicines Company’s inclisiran in Patients with Diabetes
The Medicines Company (NASDAQ: MDCO) today announced the presentation of
new data from a pre-specified, sub-group analysis of dosing, efficacy
and safety of inclisiran in patients with diabetes from the ORION-1
Phase II trial at the American Diabetes Association (ADA) 78th Scientific
Sessions® in Orlando (ADA 2018).
May 07, 2018 10:45 am ET
The Medicines Company Announces Inclisiran Data Showing Significant Reductions in Potentially Harmful Subtypes of Bad Cholesterol (Atherogenic Lipoproteins) Linked to Heart Attack and Stroke
The Medicines Company (NASDAQ:MDCO) today announced that the results of
a pre-specified analysis of secondary endpoints from the ORION-1 Phase
II study were presented at the 86th European Atherosclerosis
Society Congress (EAS 2018) and accepted for publication in Circulation,
the journal of the American Heart Association.
Apr 30, 2018 07:00 am ET
The Medicines Company Presents New Data at the National Lipid Association Scientific Sessions
The Medicines Company (NASDAQ:MDCO) presented important new data and
analyses from the ORION development program for inclisiran at the
National Lipid Association (NLA) 2018 Scientific Sessions held in Las
Vegas, NV. Multiple studies in the ORION development program demonstrate
that the proposed dosing regimen is likely to be the same for a wide
range of dyslipidemia patient populations, including those hard-to-treat
patients with homozygous familial hypercholesterolemia (HoFH) and other
sub-groups.
Apr 25, 2018 07:00 am ET
The Medicines Company Reports First-Quarter 2018 Results
The Medicines Company (NASDAQ: MDCO) today reported its financial
results for the first quarter ended March 31, 2018.
Apr 19, 2018 07:00 am ET
The Medicines Company to Announce First-Quarter 2018 Financial Results on April 25
The Medicines Company (NASDAQ:MDCO) will host a conference call and
audio webcast on Wednesday, April 25, 2018, at 8:30 a.m., Eastern Time,
to discuss first-quarter 2018 financial results and operational
developments.
Mar 27, 2018 08:05 pm ET
The Medicines Company Announces Chief Financial Officer Transition
The Medicines Company (NASDAQ: MDCO) today announced the appointment of
Christopher Visioli as Chief Financial Officer and Treasurer of the
Company, effective immediately. Mr. Visioli succeeds William B.
O’Connor, who is retiring from the Company after serving as Chief
Accounting Officer and then Chief Financial Officer for a total of 13
years. Mr. O’Connor will remain with the Company as an advisor through
2018, assisting Mr. Visioli in transition and completing the close-out
of the Company’s non-core businesses and products. Mr. Visioli will
Mar 16, 2018 07:00 am ET
The Medicines Company to Participate in the Oppenheimer 28th Annual Healthcare Conference
The Medicines Company (NASDAQ:MDCO) today announced that it will
participate in the Oppenheimer 28th Annual Healthcare
Conference on Tuesday, March 20, 2018, in New York City, NY. The Company
is scheduled to present at 08:00 a.m., Eastern Time.
Mar 08, 2018 04:30 pm ET
The Medicines Company Reaches Enrollment Target for ORION-10 Ahead of Schedule
The Medicines Company (NASDAQ: MDCO) today announced that randomization
of more than 1,500 patients in the ORION-10 trial in the United States
has been completed in only 12 weeks – considerably beating its goal of
22 weeks. ORION-10 is a double-blind, randomized Phase III trial
designed to confirm the efficacy and safety of inclisiran, an
investigational agent which is potentially a first-in-class
lipid-lowering drug to reduce LDL-cholesterol (LDL-C) in patients with
atherosclerotic cardiovascular disease (ASCVD). In the trial, patients
a
Mar 08, 2018 07:00 am ET
The Medicines Company to Participate in the Cowen 38th Annual Health Care Conference
The Medicines Company (NASDAQ:MDCO) today announced that it will
participate in the Cowen 38th Annual Health Care Conference
on Tuesday, March 13, 2018, in Boston, MA. The Company is scheduled to
present at 10:00 a.m., Eastern Time.
Feb 27, 2018 07:00 am ET
The Medicines Company Appoints Dr. Sarah Schlesinger to Its Board of Directors
The Medicines Company (NASDAQ: MDCO) today announced that its Board of
Directors has appointed Dr. Sarah Schlesinger as a new, independent
Director of the Company, effective immediately.
Feb 21, 2018 07:00 am ET
The Medicines Company Reports Fourth-Quarter and Full-Year 2017 Business and Financial Results
The Medicines Company (NASDAQ:MDCO) today reported its financial results
for the fourth quarter and full year ended December 31, 2017.
Feb 21, 2018 06:30 am ET
Medicines Company to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 21, 2018 / Medicines Company (NASDAQ: MDCO) will be discussing their earnings results in their Q4 Earnings Call to be held on February 21, 2018 at 8:30 AM Eastern Time.
Feb 20, 2018 07:00 am ET
The Medicines Company Reaches Enrollment Target for ORION-9 Ahead of Schedule
The Medicines Company (NASDAQ: MDCO) today announced that the target of
400 patients randomized in the ORION-9 trial has been exceeded in 10
weeks – considerably ahead of its anticipated recruitment goal of 24
weeks.
Feb 15, 2018 08:25 am ET
Investor Expectations to Drive Momentum within Workday, The Medicines, Celldex Therapeutics, Lannett, Oclaro, and Antares Pharma — Discovering Underlying Factors of Influence
NEW YORK, Feb. 15, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Workday, Inc. (NASDAQ:WDAY), The Medicines Company...
Feb 14, 2018 04:15 pm ET
The Medicines Company to Host Conference Call and Webcast Discussing Fourth-Quarter and Full-Year 2017 Financial Results
The Medicines Company (NASDAQ: MDCO) will host a conference call and
webcast on Wednesday, February 21, 2018, at 8:30 a.m., Eastern Time, to
discuss fourth-quarter and full-year 2017 financial results and
operational developments.
Feb 08, 2018 04:15 pm ET
The Medicines Company to Participate in the Leerink Partners 7th Annual Global Healthcare Conference
The Medicines Company (NASDAQ:MDCO) today announced that it will
participate in the Leerink Partners 7th Annual Global
Healthcare Conference on Wednesday, February 14, 2018, in New York City.
Clive Meanwell, M.D., Ph.D., Chief Executive Officer, will participate
in a fireside chat at 9:00 a.m., Eastern Time.
Jan 25, 2018 08:16 am ET
CORRECTING and REPLACING Inclisiran’s First Pivotal Trial Achieves Target Enrollment Ahead of Schedule
The end of the third sentence of the first paragraph of the release
should read: then followed to the end of the study at 540 days (18
months) (instead of: then followed to the end of the study at 510 days
(18 months)).
Jan 08, 2018 07:00 am ET
Melinta Therapeutics Completes Acquisition of The Medicines Company’s Infectious Disease Portfolio
— Expands portfolio to four marketed antibiotics, with peak sales potential over $1 billion —— Creates premier commercial stage global antibiotic franchise with the addition of Vabomere™(meropenem and vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline) for Injection —— Melinta’s FDA approved drug...
Jan 08, 2018 07:00 am ET
The Medicines Company Announces Closing of Divestiture of Infectious Disease Business Unit to Melinta Therapeutics
The Medicines Company (NASDAQ:MDCO) today announced the closing of the
sale of its infectious disease business unit to Melinta Therapeutics,
Inc. (NASDAQ: MLNT) for consideration consisting of $215 million of
guaranteed cash, approximately 3.3 million shares of Melinta common
stock, tiered royalty payments of 5% to 25% on worldwide net sales of
Vabomere™, Orbactiv® and Minocin® IV, and the
assumption by Melinta of all royalty, milestone and other payment
obligations relating to those products.
Jan 03, 2018 04:30 pm ET
The Medicines Company to Present at the 36th Annual J. P. Morgan Healthcare Conference
The Medicines Company (NASDAQ:MDCO) today announced that its Chief
Executive Officer, Clive Meanwell, M.D., Ph.D., will present at the 36th
Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018, at
8:30 a.m., Pacific Time, at The Westin St. Francis in San Francisco, CA.
A Q&A breakout session will immediately follow the presentation at 9:00
a.m., Pacific Time.
Dec 13, 2017 07:00 am ET
The Medicines Company to Host Investor Day on January 23, 2018
The Medicines Company (NASDAQ:MDCO) today announced that it will host an
Investor Day on Tuesday, January 23, 2018, from 10:00 a.m. to 12:30
p.m., Eastern Time, in New York City.
Dec 01, 2017 08:30 am ET
Report: Exploring Fundamental Drivers Behind Lannett, Oclaro, Antares Pharma, Workday, The Medicines, and Celldex Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Dec. 01, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Lannett Co Inc (NYSE:LCI), Oclaro, Inc....
Nov 29, 2017 07:00 am ET
Melinta Therapeutics Enters Into Agreement to Acquire Infectious Disease Business from The Medicines Company
- Acquisition positions Melinta as durable and focused pure-play antibiotics company with four marketed products: Baxdela®, Vabomere®, Orbactiv®, and Minocin IV® -
Nov 29, 2017 07:00 am ET
The Medicines Company Announces Definitive Agreement to Sell its Infectious Disease Business Unit to Melinta Therapeutics
The Medicines Company (NASDAQ: MDCO) today announced that it has entered
into a definitive agreement to sell its infectious disease business unit
to Melinta Therapeutics, Inc. (NASDAQ: MLNT) for $270 million in upfront
consideration and guaranteed payments ($215 million of guaranteed cash
and $55 million of Melinta common stock), tiered royalty payments of 5%
to 25% on worldwide net sales of Vabomere™, Orbactiv® and Minocin IV,
and the assumption by Melinta of all royalty, milestone and other
payment obligations relating to those products.
Nov 29, 2017 06:12 am ET
Deerfield Supports Melinta Therapeutics Acquisition of The Medicines Company's Infectious Disease Business with a $240 million Commitment to Melinta and a $100 million Commitment to The Medicines Comp
NEW YORK, Nov. 29, 2017 /PRNewswire/ -- Deerfield Management Company announced today it has committed to provide up to $240 million in debt and equity financing to Melinta Therapeutics (NASDAQ: MLNT) and up to $100 million in debt financing to The Medicines Company (NASDAQ: MDCO) in connection with Melinta's acquisition of the infectious disease business from The Medicines Company. The acquisition includes the purchase of global rights for Vabomere, Orbactiv and Minocin IV and the business unit supporting those products.
Nov 15, 2017 07:30 am ET
The Medicines Company Names Dr. Fred Eshelman as Executive Chairman; Appoints Geno Germano to Its Board of Directors
The Medicines Company (NASDAQ:MDCO) today announced that its Board of
Directors has appointed Fredric N. Eshelman, PharmD., the Company’s
current Chairman of the Board, to the newly created position of
Executive Chairman, and Geno Germano, a pharmaceutical industry
executive with over 30 years of leadership experience, as a new,
independent Director of the Company. These appointments are effective
immediately.
Nov 06, 2017 07:00 am ET
The Medicines Company and Alnylam Pharmaceuticals Announce Initiation of Phase III Clinical Trials of Inclisiran
The Medicines Company (NASDAQ: MDCO) and Alnylam Pharmaceuticals, Inc.
(NASDAQ: ALNY) today announced the initiation of the Phase III clinical
program for inclisiran, with the commencement of patient dosing on
November 1, 2017 in the ORION-11 trial, a Phase III study of inclisiran
versus placebo in patients with atherosclerotic cardiovascular disease
(ASCVD), or ASCVD-risk equivalents (e.g., type 2 diabetes and
familial hypercholesterolemia), and elevated LDL-cholesterol (LDL-C)
despite maximum tolerated doses of LDL-C lowering therapies.
Oct 25, 2017 07:00 am ET
The Medicines Company Reports Third-Quarter 2017 Business and Financial Results
The Medicines Company (NASDAQ: MDCO) today reported its financial
results for the third quarter ended September 30, 2017, and provided an
update on its clinical and operational activities.
Oct 20, 2017 07:00 am ET
The Medicines Company to Announce Third-Quarter 2017 Financial Results on October 25
The Medicines
Company (NASDAQ:MDCO) will host a conference call on Wednesday,
October 25, 2017, at 8:30 a.m., Eastern Time, to discuss its
third-quarter 2017 financial results and operational developments.
Oct 17, 2017 07:30 am ET
Corbus Pharmaceuticals Appoints Paris Panayiotopoulos to Its Board of Directors
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it has appointed Mr. Paris...
Oct 05, 2017 07:00 am ET
The Medicines Company to Present New Data from TANGO II Study of VABOMERE™ (meropenem and vaborbactam) at IDWeek 2017
The
Medicines Company (NASDAQ:MDCO) today announced that new data from
its TANGO II study of VABOMERE (meropenem and vaborbactam) will be
presented this week at IDWeek 2017 in San Diego.
Mar 03, 2017 09:41 am ET
Learn how to target a 58% return on AveXis Inc., or get option-trade ideas on Ionis Pharmaceuticals, The Medicines Co, Prothena and Tesaro Inc. or any stock you choose
CHICAGO, March 3, 2017 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVXS, IONS, MDCO, PRTA, and TSRO.
Jan 22, 2016 09:31 am ET
Covered Call Alerts For Kinder Morgan, Exxon Mobil, Skechers, Google and The Medicines Co Released By InvestorsObserver
CHICAGO, Jan. 22, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KMI, XOM, SKX, GOOGL and MDCO.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.